SUPPORTING THE DEVELOPMENT OF POTENTIAL CURES

Serial Number 97169506
Registration 7040283
700

Registration Progress

Application Filed
Dec 13, 2021
Under Examination
Approved for Publication
Feb 14, 2023
Published for Opposition
Feb 14, 2023
Registered
May 2, 2023

Basic Information

Serial Number
97169506
Registration Number
7040283
Filing Date
December 13, 2021
Registration Date
May 2, 2023
Published for Opposition
February 14, 2023
Drawing Code
4000

Status Summary

Current Status
Active
Status Code
700
Status Date
May 2, 2023
Registration
Registered
Classes
035 036 042 044

Rights Holder

HYBRID CONCEPTS INTERNATIONAL, LLC

16
Address
2135 BEDELL ROAD, SUITE 9B
GRAND ISLAND, NY 14072

Ownership History

HYBRID CONCEPTS INTERNATIONAL, LLC

Original Applicant
16
GRAND ISLAND, NY

HYBRID CONCEPTS INTERNATIONAL, LLC

Owner at Publication
16
GRAND ISLAND, NY

HYBRID CONCEPTS INTERNATIONAL, LLC

Original Registrant
16
GRAND ISLAND, NY

Legal Representation

Attorney
JOHN P. MURTAUGH

USPTO Deadlines

Next Renewal Deadline
1394 days remaining
Section 8 (6-Year) Declaration Due (Based on registration date 2023-05-02)
Due Date
May 02, 2029
Grace Period Ends
November 02, 2029
Additional deadlines exist. Contact your attorney for complete deadline information.

Application History

18 events
Date Code Type Description
May 2, 2023 R.PR A REGISTERED-PRINCIPAL REGISTER
May 2, 2023 NRCC E NOTICE OF REGISTRATION CONFIRMATION EMAILED
Feb 14, 2023 PUBO A PUBLISHED FOR OPPOSITION
Feb 14, 2023 NPUB E OFFICIAL GAZETTE PUBLICATION CONFIRMATION E-MAILED
Jan 25, 2023 NONP E NOTIFICATION OF NOTICE OF PUBLICATION E-MAILED
Jan 9, 2023 CNSA O APPROVED FOR PUB - PRINCIPAL REGISTER
Dec 28, 2022 TEME I TEAS/EMAIL CORRESPONDENCE ENTERED
Dec 27, 2022 TROA I TEAS RESPONSE TO OFFICE ACTION RECEIVED
Dec 27, 2022 CRFA I CORRESPONDENCE RECEIVED IN LAW OFFICE
Nov 17, 2022 CNRT R NON-FINAL ACTION WRITTEN
Nov 17, 2022 GNRT F NON-FINAL ACTION E-MAILED
Nov 17, 2022 GNRN O NOTIFICATION OF NON-FINAL ACTION E-MAILED
Nov 11, 2022 ZZZX Z PREVIOUS ALLOWANCE COUNT WITHDRAWN
Oct 4, 2022 PBCR Z WITHDRAWN FROM PUB - OG REVIEW QUERY
Sep 20, 2022 CNSA O APPROVED FOR PUB - PRINCIPAL REGISTER
Sep 19, 2022 DOCK D ASSIGNED TO EXAMINER
Dec 16, 2021 NWAP I NEW APPLICATION ENTERED
Dec 16, 2021 NWOS I NEW APPLICATION OFFICE SUPPLIED DATA ENTERED

Detailed Classifications

Class 035
Assistance, advisory services and consultancy with regard to business planning; Business consulting and management in the field of clinical trials, namely, clinical data and regulatory submission management on behalf of medical, biopharmaceutical and biotechnology companies to assist them with clinical research, clinical trials and applications for drug approval; Business consulting services; Business consulting services in the field of potential medical cures including cell and gene therapies; Business consultation in the field of cell therapy, gene therapy, gene editing, xenotransplantation, regenerative medicine, advanced therapies, advanced therapeutic medicinal products, biologics, pharmaceuticals, medical devices, regulatory affairs including preclinical, clinical and commercial stage, pharmaceutical preclinical and clinical research, development, chemistry, manufacturing and controls, and quality assurance/quality control; Business consulting services, namely, providing assistance in development of business strategies and creative ideation; Business management consulting and advisory services; Business support services, namely, business consulting to freelancers, start-ups, existing businesses and non-profit organizations; Consultancy and advisory services in the field of business strategy; Consulting services in the field of medical product approval for commercial purposes; International business consulting services relating to USA and outside of USA product, clinical and commercial development of investigational or approved medical products; New business venture development and formation consulting services; Promoting the exchange of information and resources within the scientific research communities to achieve advances in the field of 21st century transformational science; Providing consulting services in the field of regulatory submission management to medical companies to assist them with applications for medical device approval; Providing independent review of clinical trials for business purposes; Promoting technical and scientific investigation, research and experimentation in the field of scientific discovery through support of educational institutions and scientific organizations
First Use Anywhere: Dec 9, 2021
First Use in Commerce: Dec 9, 2021
Class 036
Financial consulting services, namely, advising others regarding intellectual property investments; Investment consultation in the fields of product, technical, regulatory, preclinical, clinical, and commercial diligence for innovative potential or investigational medical products
First Use Anywhere: Dec 9, 2021
First Use in Commerce: Dec 9, 2021
Class 042
Consulting services in the fields of biotechnology, pharmaceutical research and development and genetic science; Consulting services in the fields of biotechnology, pharmaceutical research and development, laboratory testing, diagnostics, and pharmacogenetics; Medical and scientific research information in the field of cell therapy, gene therapy, gene editing, xenotransplantation, regenerative medicine, advanced therapies, advanced therapeutic medicinal products, biologics, pharmaceuticals, medical devices, regulatory affairs including preclinical, clinical and commercial stage, pharmaceutical preclinical and clinical research, development, manufacturing/CMC and quality assurance/quality control; Providing information about medical and scientific research; Providing information on the subject of scientific research in the field of biochemistry and biotechnology; Providing medical and scientific research information in the field of clinical trials; Providing medical and scientific research information in the fields of pharmaceuticals and genetics; Scientific and technological services, namely, scientific research in the field of cell therapy, gene therapy, gene editing, xenotransplantation, regenerative medicine, advanced therapies, advanced therapeutic medicinal products, biologics, pharmaceuticals, medical devices, scientific research for preclinical, clinical and commercial stage pharmaceuticals, pharmaceutical preclinical and clinical research, development, and quality assurance/quality control; Scientific research consulting in the field of cell therapy, gene therapy, gene editing, xenotransplantation, regenerative medicine, advanced therapies, advanced therapeutic medicinal products, biologics, pharmaceuticals, medical devices, scientific research for preclinical, clinical and commercial stage pharmaceuticals, pharmaceutical preclinical and clinical research, development, and quality assurance/quality control; Scientific research and development; Technological planning and consulting services in the field of cell therapy, gene therapy, gene editing, xenotransplantation, regenerative medicine, advanced therapies, advanced therapeutic medicinal products, biologics, pharmaceuticals, medical devices, scientific research for preclinical, clinical and commercial stage pharmaceuticals, pharmaceutical preclinical and clinical research, development, and quality assurance/quality control; Testing, inspection, research, or development of pharmaceutical preparations for gene therapy; Providing medical and scientific research information in the field of pharmaceuticals and clinical trials; Scientific consulting and research services relating to foods and dietary supplements; Scientific research consulting in the field of cosmetics
First Use Anywhere: Dec 9, 2021
First Use in Commerce: Dec 9, 2021
Class 044
Consulting services in the field of health; Consulting services to health care providers in the field of treating life-changing or life-threatening diseases
First Use Anywhere: Dec 9, 2021
First Use in Commerce: Dec 9, 2021

Classification

International Classes
035 036 042 044